Single User License
INR 133440
Site License
INR 266880
Corporate User License
INR 400320

Service Tax Additional

select a format

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000


Request a quote
Request a Customized research
Request for Sample Report

Recent Viewed Reports

Why Ken Reasearch?


While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"

Pre-Eclampsia-Pipeline Review, H1 2015

Pre-Eclampsia-Pipeline Review, H1 2015

  • Products Id :- GMDHC6311IDB
  • |
  • Pages: 50
  • |
  • February 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Pre-Eclampsia-Pipeline Review, H1 2015


Global Markets Direct's, 'Pre-Eclampsia-Pipeline Review, H1 2015', provides an overview of the Pre-Eclampsia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pre-Eclampsia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pre-Eclampsia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Pre-Eclampsia

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Pre-Eclampsia and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Pre-Eclampsia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Pre-Eclampsia pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Pre-Eclampsia

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Pre-Eclampsia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Pre-Eclampsia Overview 6

Therapeutics Development 7

Pipeline Products for Pre-Eclampsia-Overview 7

Pipeline Products for Pre-Eclampsia-Comparative Analysis 8

Pre-Eclampsia-Therapeutics under Development by Companies 9

Pre-Eclampsia-Therapeutics under Investigation by Universities/Institutes 10

Pre-Eclampsia-Pipeline Products Glance 11

Late Stage Products 11

Clinical Stage Products 12

Early Stage Products 13

Pre-Eclampsia-Products under Development by Companies 14

Pre-Eclampsia-Products under Investigation by Universities/Institutes 15

Pre-Eclampsia-Companies Involved in Therapeutics Development 16

A1M Pharma AB 16

Alnylam Pharmaceuticals, Inc. 17

Glenveigh Medical, LLC 18

Pluristem Therapeutics Inc. 19

rEVO Biologics 20

VG Life Sciences, Inc. 21

Pre-Eclampsia-Therapeutics Assessment 22

Assessment by Monotherapy Products 22

Assessment by Target 23

Assessment by Mechanism of Action 25

Assessment by Route of Administration 27

Assessment by Molecule Type 29

Drug Profiles 31

ALN-AGT-Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

Alpha-1-Microglobulin-Drug Profile 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

antithrombin alfa (recombinant)-Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

digoxin immune fab-Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

Monoclonal Antibodies for Cardiovascular Diseases-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction-Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

Stem Cell Therapy for Pre-Eclampsia-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

VG-1177-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

Pre-Eclampsia-Recent Pipeline Updates 40

Pre-Eclampsia-Dormant Projects 42

Pre-Eclampsia-Product Development Milestones 43

Featured News & Press Releases 43

Sep 12, 2014: Alnylam Broadens Pipeline with ALN-AGT, a Subcutaneously Administered RNAi Therapeutic Targeting Angiotensinogen for the Treatment of Hypertensive Disorders of Pregnancy, Including Preeclampsia 43

Sep 10, 2014: Pluristem to Deliver Scientific Presentations at 3rd International Placenta Stem Cell Society Meeting 44

Jul 23, 2014: rEVO Biologics Announces Enrollment of First Patient in Phase 3 Trial of ATryn to Treat Early Onset Preeclampsia (PRESERVE-1) 44

Jul 08, 2014: Orphan Drug Designation Granted in Europe for A1M Pharma's Treatment for Preeclampsia 45

Mar 31, 2014: rEVO Biologics Initiates PRESERVE-1 Phase 3 Clinical Trial for ATryn in Early-Onset Preeclampsia 46

Feb 25, 2014: rEVO Biologics Announces the Submission of an IND for ATryn in Preeclampsia 46

Feb 20, 2014: Pluristem Submits FDA Orphan Drug Application for Preeclampsia 47

Nov 04, 2013: Safety of Pluristem's PLX Cells Demonstrated in Pre-Clinical Pregnancy Model 48

Appendix 49

Methodology 49

Coverage 49

Secondary Research 49

Primary Research 49

Expert Panel Validation 49

Contact Us 49

Disclaimer 50

List of Tables

Number of Products under Development for Pre-Eclampsia, H1 2015 7

Number of Products under Development for Pre-Eclampsia-Comparative Analysis, H1 2015 8

Number of Products under Development by Companies, H1 2015 9

Number of Products under Investigation by Universities/Institutes, H1 2015 10

Comparative Analysis by Late Stage Development, H1 2015 11

Comparative Analysis by Clinical Stage Development, H1 2015 12

Comparative Analysis by Early Stage Development, H1 2015 13

Products under Development by Companies, H1 2015 14

Products under Investigation by Universities/Institutes, H1 2015 15

Pre-Eclampsia-Pipeline by A1M Pharma AB, H1 2015 16

Pre-Eclampsia-Pipeline by Alnylam Pharmaceuticals, Inc., H1 2015 17

Pre-Eclampsia-Pipeline by Glenveigh Medical, LLC, H1 2015 18

Pre-Eclampsia-Pipeline by Pluristem Therapeutics Inc., H1 2015 19

Pre-Eclampsia-Pipeline by rEVO Biologics, H1 2015 20

Pre-Eclampsia-Pipeline by VG Life Sciences, Inc., H1 2015 21

Assessment by Monotherapy Products, H1 2015 22

Number of Products by Stage and Target, H1 2015 24

Number of Products by Stage and Mechanism of Action, H1 2015 26

Number of Products by Stage and Route of Administration, H1 2015 28

Number of Products by Stage and Molecule Type, H1 2015 30

Pre-Eclampsia Therapeutics-Recent Pipeline Updates, H1 2015 40

Pre-Eclampsia-Dormant Projects, H1 2015 42

List of Figures

Number of Products under Development for Pre-Eclampsia, H1 2015 7

Number of Products under Development for Pre-Eclampsia-Comparative Analysis, H1 2015 8

Number of Products under Development by Companies, H1 2015 9

Number of Products under Investigation by Universities/Institutes, H1 2015 10

Comparative Analysis by Clinical Stage Development, H1 2015 12

Comparative Analysis by Early Stage Products, H1 2015 13

Assessment by Monotherapy Products, H1 2015 22

Number of Products by Top 10 Targets, H1 2015 23

Number of Products by Stage and Top 10 Targets, H1 2015 24

Number of Products by Top 10 Mechanism of Actions, H1 2015 25

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 26

Number of Products by Top 10 Routes of Administration, H1 2015 27

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 28

Number of Products by Top 10 Molecule Types, H1 2015 29

Number of Products by Stage and Top 10 Molecule Types, H1 2015 30

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@]

A1M Pharma AB

Alnylam Pharmaceuticals, Inc.

Glenveigh Medical, LLC

Pluristem Therapeutics Inc.

rEVO Biologics

VG Life Sciences, Inc.

Pre-Eclampsia Therapeutic Products under Development, Key Players in Pre-Eclampsia Therapeutics, Pre-Eclampsia Pipeline Overview, Pre-Eclampsia Pipeline, Pre-Eclampsia Pipeline Assessment

Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204


Company Brochure

Engage with Us

query [@]